TOI · The Oncology Institute, Inc. · Stock research

Current Thesis

Two things happened after the last read that change the shape of this name. First, on 2026-08-03 the company announced a rebrand to Starling Oncology, Inc., and the shares began trading on Nasdaq under STLN on 2026-08-04, replacing TOI. The graded reference series under the legacy symbol therefore ends at the 2026-08-03 close of $5.13 — anyone tracking this name has to follow the new symbol to see what the tape has done since.

Second, the Q2 print landed 2026-08-06, six days earlier than the previously flagged 8/12 date, and it went the right way on the lines that matter for a capitation pivot. Revenue $161.282M against a $155.193M consensus, +34.6% YoY. Adjusted EBITDA turned positive at $0.2M versus a $4.1M loss a year earlier. FY26 revenue guidance moved up to $650–670M from $630–650M, gross-profit guidance to $105–110M from $97–107M, and the adjusted-EBITDA range was narrowed to $2–7M from $0–9M — the floor lifted off breakeven. GAAP EPS still missed at $(0.08) versus $(0.06) estimated.

The narrative leg on offer is the same one the 2026-07-09 OrbiMed refinancing opened: a value-based oncology operator that has removed its 2027 maturity wall without issuing equity, is now printing positive adjusted EBITDA, and is carrying delegated-risk contracts outside Florida for the first time. What has not happened is a price structure that confirms it. The mid-July spike round-tripped, and RSI(14) was 32.0 into the print.

Bullish and bearish views on The Oncology Institute, Inc.

The model's bull view on The Oncology Institute, Inc. (TOI), in brief: First positive adjusted-EBITDA quarter as a public company (Q2, reported 2026-08-06): +$0.2M versus $(4.1)M in Q2'25. The bear view: The July breakout failed and never rebuilt. Both cases follow in full.

Bull Case

• First positive adjusted-EBITDA quarter as a public company (Q2, reported 2026-08-06): +$0.2M versus $(4.1)M in Q2'25. Gross profit $27.2M at a 16.8% margin, +225bps YoY. Year-to-date free cash flow $9.5M against a full-year guide of $5–15M, meaning the FCF guide is already covered on a YTD basis.
• Guidance raised, not reaffirmed. FY26 revenue $650–670M (from $630–650M), gross profit $105–110M (from $97–107M), adjusted EBITDA $2–7M (from $0–9M), FCF $5–15M, with roughly $150M of capitated revenue expected in the year.
• Geographic proof point. Three new delegated contracts launch in Q4 2026, including the first expansion outside Florida — Nevada and Oregon, roughly 80,000 lives — plus a California exclusivity win covering about 230,000 lives at approximately $6M of annualized capitation. Until this print the delegated story was a single-state story.
• Balance sheet cleared through 2031. The 2026-07-09 refinancing retired the $86M Deerfield senior secured convertible with a $75M OrbiMed term loan maturing 2031-07-01 (greater of 3% or SOFR+5.75%) plus roughly $11M of cash, with no equity issued. Cash stood at $41.1M at quarter-end.
• The July 21 tranche was bought after the spike broke, not into it.
• Published targets sit above the tape. Lake Street initiated Buy at $10 on 2026-07-06; BTIG went $8→$9 on 2026-07-09; B. Riley $8; Needham $7 on 2026-06-17. No post-Q2 revisions were confirmed as of 2026-08-15.

Bear Case

• The July breakout failed and never rebuilt. Call volume of 25,717 contracts against a 1,030 average on 2026-07-09 (+2,397%) marked the top of the flow, price reached the $6.28 fifty-two-week high on the adjusted series, and the last completed print under the old symbol was $5.13 on 2026-08-03 — 18.3% below that high, with RSI(14) at 32.0. Retail and options flow arrived before the fundamentals confirmed.
• The beat was a mix beat. Specialty Pharmacy contributed $98.6M of the $161.3M in Q2 revenue, growing 57.6%. Dispensary volume carries a far lower margin than delegated capitation, which is why a 34.6% revenue line still produced a $(0.08) GAAP loss and a 16.8% consolidated gross margin.
• Medical loss ratio has no cushion. Q2 MLR was 85.5%, inside a stated near-term expectation of 80–90% but well above the 75–85% full-ramp target. Onboarding ~80,000 new lives in Q4 typically raises MLR before it falls; a $2–7M EBITDA guide does not absorb much of that.
• Interest expense is now floating. $75M at the greater of 3% or SOFR+5.75% pushes front-end rate moves straight into the P&L against an EBITDA base guided at $2–7M. The old convertible did not do that.
• Symbol change is a mechanical liquidity risk. Screens, watchlists, retail broker tickers and some data feeds re-map on a lag after a 2026-08-04 change. For a name with roughly $10M in average daily dollar volume as reported in mid-July, that is a real, if temporary, thinning of the bid.
• Cybersecurity cost is still unquantified. The November 2025 incident and the 2026-05-22 follow-up confirming a software service provider had unauthorized access to information have not been paired with a disclosed remediation charge.

Setup & Price Structure

The tradable series discontinuity is the first structural fact: the last completed daily close under TOI was $5.13 on 2026-08-03, one session before the STLN change and three before the print. Anything about post-print price action belongs to the new symbol and is not in the legacy series. The 50-day near $4.90; the 200-day near $3.78, rising all year. Three-month return was +25.7% into 2026-08-03, so the July advance had not been given back — but RSI(14) at 32.0 with price 18.3% under the high describes a name that sold off into its own catalyst rather than one being accumulated ahead of it.

Positioning observables, stated without a verdict: short interest around 11% of float with a roughly 3.5-day cover ratio and a float near 57.7M of about 100M shares outstanding, as reported in mid-July; a 24x single-day call-volume spike on 2026-07-09; five insider buy tranches between 2026-05-20 and 2026-07-21 against one 10b5-1 sale (CMO Yale Podnos, 23,451 @ $5.38 on 2026-06-08); and analyst targets in a $7–$10 band set in June and July, all above the last legacy close.

The narrative is maturing. The attention burst is behind it — the initiation and upgrade cluster ran 2026-07-06 to 2026-07-09, the options blowout was 2026-07-09, and the failed breakout completed by 2026-07-17. The fundamental narrative kept working through 2026-08-06 (guidance raise, first positive adjusted EBITDA, out-of-state delegated contracts), but the flow that would mark accelerating — expanding volume, fresh coverage, new participants — is not evidenced after mid-July. It is not saturated: coverage remains four to six firms and there is no mainstream retail wave visible after the July options print.

Catalyst Calendar (next 30 days)

• ~2026-11-05 (est.) — Q3 FY26 results. Cadence: Q1 reported mid-May, Q2 on 2026-08-06. First quarter in which the $2–7M FY26 adjusted-EBITDA floor and the raised $650–670M revenue guide face a full quarter of new capitated onboarding costs.
• Q4 2026, ~2026-10-01 (est.) onward — go-live of three new delegated contracts, including Nevada and Oregon (~80,000 lives). First evidence on whether delegated economics travel outside Florida.

Elapsed catalysts

• No scheduled company catalyst inside 30 days. The Q2 print (2026-08-06) and the symbol change (2026-08-04) have both come and gone; the next scheduled gate is the Q3 report. (passed 20d ago)
• Ongoing, undated — Form 4 filings from the 10% owner. Five open-market tranches in the 2026-05-20 to 2026-07-21 window; a sixth, or its absence, is observable in real time on EDGAR. (passed 36d ago)

What Would Change Our Mind

The structure to watch is whether the July advance survives at all. The $5.30–5.35 shelf already failed once, so the load-bearing level is the 50-day near $4.90: losing it on a weekly close below $4.90 would erase the entire price response to the 2026-07-09 refinancing and the analyst cluster that followed, leaving a name whose only support is a 200-day near $3.78.

Second, on fundamentals: the FY26 adjusted-EBITDA floor was just lifted to $2M. A Q3 guide that pushes that floor back to or below zero, or that cuts the $5–15M free-cash-flow range while $75M of floating-rate debt accrues at SOFR+5.75%, would break the "first profitable year" leg regardless of price.

Third, on the operating thesis: Q2 MLR of 85.5% sits in the upper half of the stated 80–90% near-term band. A Q3 MLR above 90%, or a sequential decline in capitated revenue against the ~$150M full-year expectation, would say the delegated model is scaling lives faster than it is scaling margin.

Fourth, on timing: if the Q4 Nevada/Oregon go-lives slip past the Q3 call without a new date, the out-of-Florida proof point moves to 2027 and the 2028 delegated-economics story gets a year longer.

Conversely, the read strengthens on a reclaim of the $5.30–5.35 shelf and then the $6.28 high on expanding volume under the new symbol, with a sixth insider tranche and any post-Q2 target revision above the June–July $7–$10 band.

Correlation Notes

• Delegated-risk peer group. Trades with the Medicare Advantage provider-risk complex — Astrana Health, Privia, agilon health, Evolent — which moves on MA cost-trend commentary and CMS rate-notice cycles more than on any single operator's revenue line. A utilization scare at a larger peer re-prices this whole cohort regardless of company-specific delegated performance.
• Drug-dispensing exposure. With Specialty Pharmacy at $98.6M of $161.3M in Q2 revenue, the top line is partly a drug-distribution business and carries sensitivity to oral-oncolytic pricing and Part D reimbursement design, which is a different driver from capitated medical margin.
• Front-end rates. The $75M OrbiMed term loan at the greater of 3% or SOFR+5.75% makes interest expense a direct function of short-rate policy against a $2–7M guided EBITDA base — an unusually tight linkage for a small-cap provider.
• Small-cap liquidity beta. Roughly $10M in average daily dollar volume as of mid-July, an ~11% short interest and a float near 57.7M shares mean Russell-2000-level risk-off moves and the post-2026-08-04 symbol re-mapping both hit the bid harder than the underlying operating news would justify.